Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA

Walter Stummer(University of Münster), Uwe Pichlmeier(Medac (Germany)), Florian Stockhammer(Medizinische Hochschule Hannover), Giles H. Vince(Klinikum Aschaffenburg), Bodo Christian Kern(BG Klinikum Bergmannstrost Halle), Dietmar Krex, H. M. Mehdorn(University Hospital Schleswig-Holstein), Ulf Nestler(Leipzig University)

Journal of Neuro-Oncology

October 4, 2010

10.1007/s11060-010-0400-9

Cited by 78

Related Papers

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

|The Lancet Oncology|2006|3.4k

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

|Neurosurgery|2008|1k

Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patients

|Journal of neurosurgery|2000|880

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

|The Lancet|2019|581

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

|Journal of Translational Medicine|2018|540